23andMe appoints ex-Genentech exec to lead new therapeutics unit
This article was originally published in Scrip
23andMe has created a new therapeutics unit and appointed Dr Richard Scheller chief science officer and head of therapeutics in order to lead it. Dr Scheller retired in December 2014 after 14 years at Genentech where he was the executive vice-president of research and early development.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.